Gynuity Health Projects—a pro-abortion research group working to increase access to the abortion pill—wants the pill used to treat conditions unrelated to abortion. Getting the abortion pill approved to treat medical conditions means it will be easier to get the pill into countries where abortion is illegal, and where the abortion pill is banned.
Reproductive Health Supplies Coalition (RHSC) revealed this strategy in a webinar, which includes a presentation and video. Gynuity received a $108k grant from the RHSC’s Innovation Fund to conduct “a landscape analysis that will identify market gaps, bottlenecks, and potential country-level opportunities to register and commercialize mifepristone for its other indications.”
Formed in 2004, RHSC took off in 2012 when it became involved in the Gates-funded Family Planning 2020 initiative. The coalition includes the Bill and Melinda Gates Foundation, the Bixby Center for Global Reproductive Health, the David and Lucile Packard Foundation, DKT International, GenBioPro, the Guttmacher Institute, Ibis Reproductive Health, Planned Parenthood, and the Population Council. Its current executive committee includes representatives from the Population Council, the Bill and Melinda Gates Foundation, Planned Parenthood Federation of America, and the United Nations Population Fund.
Jennifer Blum, Gynuity’s VP for Programs and Strategic Initiatives, and former Program Officer for the Packard Foundation—a major early investor in the manufacturer of the abortion pill—said in the webinar that registering the abortion pill to treat conditions unrelated to abortion is to “bypass hurdles.” Blum noted, “The number of countries with mifepristone [the abortion pill] is increasing but in places with restrictive abortion laws, access remains challenging.”
Read more at Live Action >>